University of California, Davis
May 23, 2007
AIRMID LICENSED TO DEVELOP CANDIDATE DRUGS
Two exclusive licensing agreements to commercialize potential treatments for multiple sclerosis and psoriasis have just been completed by UC Davis InnovationAccess and Airmid Inc., a startup company based in Redwood City, Calif.
The agreements cover patents held by UC Davis and UC Irvine on two novel compounds that could be used to treat autoimmune diseases, in which the body's own immune system attacks healthy tissue. The agreements allow Airmid to pursue further testing and commercial development of the compounds.
"Airmid is the latest of the startup companies emerging from the UC campuses -- in this case from both UC Davis and UC Irvine. I'm delighted we've concluded this license with the company, and look forward to their growth and success," said David McGee, executive director of UC Davis InnovationAccess.
"We at Airmid are extremely excited about the prospect of working with the University of California and its world-renowned researchers to bring these potential therapies to the millions of sufferers of autoimmune diseases, who so desperately need safer and more effective treatments," said Airmid CEO George Miljanich.
The first compound, ShK(L5) is a synthetic version of a component of sea anemone venom. It prevents the activity of human immune cells that are implicated in conditions such as multiple sclerosis and is effective in animal models of multiple sclerosis and rheumatoid arthritis.
The second, PAP-1, is derived from a shrub, the common rue. In the laboratory, it can suppress skin inflammation in rats. It could have potential as a treatment for psoriasis.
Both compounds act to block channels that allow potassium ions to flow in or out of cells. These ion channels appear to play an important role in regulating the activity of cells in the immune system and are especially abundant on a type of immune cell implicated in diseases such as multiple sclerosis and psoriasis.
"This could be a completely new mechanism of immune suppression for patients who do not respond to or have side effects from current therapies," said UC Davis' Heike Wulff, assistant professor of medical pharmacology and toxicology.
The compounds were discovered by Wulff and George Chandy, professor of physiology and biophysics at UC Irvine, as a result of work in Chandy's laboratory going back more than two decades. Chandy and Wulff are also among the co-founders of Airmid.
Both compounds have been tested in the laboratory but not yet studied in humans. UC Davis' InnovationAccess unit negotiated the licensing agreements on behalf of both campuses.
Airmid is a privately held pharmaceutical company based in Redwood City, Calif. Airmid is focused on developing its novel potassium ion channel blockers as safer and more effective medicines for a variety of autoimmune diseases that are inadequately treated by current therapies. These diseases include multiple sclerosis, psoriasis, type
1 diabetes and rheumatoid arthritis.
About UC Davis InnovationAccess
UC Davis InnovationAccess actively manages a patent portfolio of 841 inventions reflecting the diversity of the campus's research base, and seeks opportunities to commercialize these via licensing, with
485 currently active licensees. UC Davis has also seen an upsurge in startup companies emerging from campus research and technologies, with nearly 20 companies founded since 2005. The UC Davis InnovationAccess team is comprised of more than 20 professionals with PhDs, JDs, and MBAs with significant private-sector experience.
Wednesday, May 23, 2007
- New Date At Strait
- School District Celebrates Twin Achievements
- Lagoon Valley Developer Seeks Wetlands Permit
- Tahoe Artist Tapped To Paint Mural
- Touro's 'Village' Concept Praised
- Solano EDC Hosts Event
- Suisun Valley Co-op Aims For Niche In Wine Market
- Come Share The 'Joy of Eating' At Restaurant
- New Suisun Restaurant To Feature California French...
- Agency Wins Award For Laurel Gardens Project
- AIRMID LICENSED TO DEVELOP CANDIDATE DRUGS FROM UC...
- UC Davis licenses autoimmune patents
- The Sacramento Region is showing improving job gro...
- Wal-Mart Victorious In AmCan
- Supes: Marketing Could Help Vineyards
- Fairfield Recognized With National Housing Award
- City Wants Mural To Paint Positive Image
- Agro-Tourism Seeds Planted
- Supervisors To Hear Study Touting Appeal Of Suisun...
- Paradise Expands
- 10 Questions With Charles Eason
- Complicated Growth Issues Face Solano
- $50,000-per-year GREAT grants stimulate and suppor...
- San Jose area ranks tops for nanotech
- Suisun City Plans To Dredge Up Harbor
- Vacaville Revives VIP Day, A Development Sales Pit...
- Vacaville: 'Great Hub For Businesses'
- Counties, Caltrans agree to co-manage Highway 12 p...
- Bay Area execs see job growth
- Mercedes-Benz To Set Up Shop In Auto Mall
- Whales Wend Their Way To Rio Vista
- City to Roll Red Carpet For Investors
- Farmer Teams Up With Raley's to Sell Home-Grown Oi...
- Report Shows Employment Up in Solano
- Affordable and Green
- Oil's Future
- Refinery owners upgrading for more reliability, pr...
- Aviators Told of Nut Tree's Coming Phase
- Vacaville On Display For Visiting VIPs
- Travis Funding Part of Defense Appropriation
- Fentons to Open Ice Cream Parlor at Nut Tree Park
- Touro Moves Quickly on M.I. Village
- City to Seek Aid For Clean Fleet's Sustainance
- Supervisors OK Homeless Shelter Donation of $1M
- Developer Touts Wine-Country Living at Affordable ...
- County to Contribute $1M to Mission Solano
- ▼ May (46)
- ► 2006 (662)
- ► 2005 (627)
- ► 2004 (125)